HANSHOW
14.8.2024 15:01:34 CEST | Business Wire | Press release
Hanshow, a global leader in developing and manufacturing electronic shelf labels (ESLs) and digital store solutions, proudly announces its recognition as a Sample Vendor in the Gartner Hype Cycle for Retail Technologies, 2024, under the Smart Shelf category, as well as in the Gartner Hype Cycle for Wireless Technology, 2024, under the Bluetooth ESL category. The Gartner Hype Cycle reports evaluate the maturity and adoption of various retail technologies, providing valuable insights for retail CIOs to make informed investment decisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807460853/en/
Hanshow‘s Holistic Green Store Solutions (Graphic: Business Wire)
According to the 2024 Hype Cycle for Retail Technologies report, “Smart shelves can provide critical real-time visibility to in-store, on-shelf availability; increase operational efficiency; guide customers and associates to discover products; and contribute inputs to Internet of Things (IoT)-based real-time store monitoring capabilities. Data from smart shelves can equip retailers to replicate a richer in-store experience, generating revenue uplift and delivering significant efficiency gains of store operations.”
Hanshow’s smart shelf technology and ESLs are positioned as high benefit innovations that are set to mature and gain widespread adoption within the next five to ten years. Hanshow’s smart shelf solutions integrate an advanced SaaS IoT management platform with devices such as ESLs and digital marketing to provide real-time inventory management, dynamic pricing, and customer engagement.
Hanshow was also recognized as a sample vendor in the 2024 Hype Cycle for Wireless Technologies under the Bluetooth ESL category. Bluetooth ESLs are highlighted by the report as a significant innovation - emerging technology with a high benefit rating and is expected to reach mainstream adoption within two to five years.
These capabilities significantly improve the efficiency of in-store operations and enhance the overall shopping experience and operational efficiency. ESLs are recognized for their ability to facilitate real-time, data-driven pricing and product information updates, crucial for retailers aiming to synchronize their digital and physical channels. Inclusion as a Sample Vendor in these Gartner Hype Cycle reports underscores Hanshow’s position as a leading innovator in the industry.
“We are honored to be recognized by Gartner as a Sample Vendor in the 2024 Hype Cycle for Retail Technologies and 2024 Hype Cycle for Wireless Technologies,” said Shiguo Hou, CEO of Hanshow. “This recognition validates our efforts in pioneering digital store solutions that help retailers optimize their operations, enhance customer engagement, and achieve sustainable growth.”
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
Gartner Disclaimer:
Gartner, Hype Cycle for Retail Technologies, 2024, By Analysis Sandeep Unni, Max Panther Hammond, Published 29 July 2024
Gartner, Hype Cycle for Wireless Technologies, 2024, Analysis By Nick Jones, Published 5 August 2024
Gartner does not endorse any vendor, product, or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807460853/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom